InflaRx N.V.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsInflaRx N.V. is a clinical-stage biopharmaceutical company developing complement-targeted therapies, listed on Nasdaq under the symbol IFRX.
What they do
InflaRx N.V. is a Netherlands-incorporated biopharmaceutical company with principal operations in Jena, Germany. It is focused on the discovery, clinical development and potential commercialization of inhibitors of the complement system, particularly of the complement factor C5a and its receptor C5aR. The company's ordinary shares are listed on The Nasdaq Stock Market LLC under the trading symbol IFRX.
Recent performance
The provided excerpts do not include consolidated statements of operations or revenue figures for the fiscal year ended December 31, 2025. The company reported 72,292,859 outstanding ordinary shares as of December 31, 2025. No product revenue, licensing revenue or grant income is disclosed in the excerpts.
Strategy
The provided excerpts do not include management's discussion and analysis of financial condition and results of operations, nor a business overview describing strategy, programs or pipeline priorities. The filing table of contents indicates that research and development activities, patents and licenses are addressed in Item 5.D of the annual report, but that content is not included in the excerpts.
Risks
- Clinical-stage dependency — The excerpts do not identify any approved product or commercial revenue, so the company's prospects depend on the success of its development programs.
- Regulatory and development uncertainty — As a pharmaceutical preparations company filing a Form 20-F, the company is subject to the risks inherent in obtaining regulatory approvals, but no specific program or regulatory milestone is described in the excerpts.
- Limited disclosure in excerpts — The excerpts omit the risk factors section, so company-specific risks beyond those typical for clinical-stage biopharmaceutical companies cannot be enumerated here.
- Foreign private issuer status — The company reports as a foreign private issuer incorporated in the Netherlands, which affects the form and frequency of disclosures compared with U.S. domestic issuers.
Outlook
The provided excerpts do not include forward-looking statements or management guidance regarding future periods. No anticipated milestones, trial readouts or commercialization timelines are described in the available text.